confirmed a CD34+, CD117+ immature myeloid population. Cytogenetics showed the following karyotype: 46,XX,inv(17)(p3q11.2)[1]/s1,-12,+mar1[6]/sdl, t(9;22) (q34;q11.2) [3] . RT-PCR revealed a p190 BCR/ABL fusion transcript. Therapy included dasatinib, cytarabine, and idarubicin. The patient achieved inadequate induction with persistent clinical disease at 18 months with detectable BCR-ABL transcripts in peripheral blood. Discussion: Currently there is no standardized treatment for BCR-ABL+ AML, yet differential diagnosis is important to ensure appropriate therapy. Specific cytogenetic abnormalities such as inv(3) or complex karyotypes, in conjunction with the limited presence of the Philadelphia chromosome and the p190 fusion transcript, which is rare in CML, supported a diagnosis of AML. Despite similar morphologic characteristics and therapy, our patients had different outcomes highlighting the need to systematically investigate this rare subtype of AML. Introduction: Acute promyelocytic leukemia and hairy cell leukemia are two distinct hematologic malignancies. Coexistence of these two pathologies has not been reported previously.
Methods:
We report a case of a 69-year-old woman from Grenada who presented with pancytopenia. Laboratory findings, morphology, immunophenotyping, mutational analysis, and cytogenetic investigation supported the diagnosis of acute promyelocytic leukemia, including PML/ RAR gene rearrangement and t(15;17)(q24;q21.2) in support of the diagnosis. In a fraction of the bone marrow content, however, the morphology and immunophenotyping indicated that the coexisting neoplasia is hairy cell leukemia. We did not find any treatment-related effect that could have contributed to the development of coexisting acute promyelocytic leukemia and hairy cell leukemia. Conclusions: At present, management is focused on treating the acute promyelocytic leukemia and monitoring the hairy cell leukemia. The clonal relationship between these two neoplasias is under investigation by using cell linage specific interphase cytogenetic analysis. Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease (SM-AHNMD) is a rare hematopoietic malignancy. We present a 60-year-old African woman with history of psoriasis who presented with nonproductive cough, diarrhea, and dark stools. Blood work showed pancytopenia with mild eosinophilia. Stool examination ruled out parasitic infection. Peripheral blood smear showed few atypical cells and eosinophilia. Flow cytometry of the peripheral blood showed 7% myeloblast. Subsequent bone marrow examination showed a normocellular marrow with an M:E ratio of 5:1. Myeloid maturation was left shifted with 45% myeloblasts. There were scattered interstitial aggregates of small to medium-sized, spindle-shaped cells with eosinophilic cytoplasm, which were positive for tryptase, CD117, and CD25 on immunohistochemistry confirming them to be mast cells. Serum tryptase levels were high (15.8 ng/mL). Flow cytometry showed increase in myeloblasts that were positive for CD34, CD117, CD33, HLA-DR, and CD56. CEBPA mutational analysis was positive. Fluorescent in situ hybridization for common acute myeloid leukemia and myelodysplastic syndrome related translocations and mutational analysis for prognostic markers including NPM1, FLT3 and c-kit D816V were negative. Based on the bone marrow morphology and immunophenotyping, the patient was diagnosed to have SM-AHNMD, with the AHNMD component being CEBPA-positive AML. Patient was started on chemotherapy with cytarabine and daunorubicin. A repeat bone marrow examination after the induction chemotherapy showed residual myeloblasts of 16% and focal mast cell aggregates consistent with residual SM-AHNMD. The patient was started on re-induction regimen with mitoxantrone, etoposide and cytarabine. Bone marrow examination after re-induction was negative for residual blasts (<1%) and showed rare scattered mast cells (1%-2%). The patient achieved remission and CEBPA mutation analysis turned negative. The prognosis of SM-AHNMD depends on the non-mast cell malignancy and SM-AML is considered to have poor prognosis. Our patient is in continued remission so far. MD, Humayun Islam, MD, PhD, Faisal Saeed, MD, Fouzia Shakil, MD, PhD; Westchester Medical Center, Valhalla, NY 
